Global /United States /Healthcare /Medical Devices /RTGN

RetinalGenix Technologies Inc.

RTGN

• OTCMKTS: RTGN • Delayed

3.20USD -9.9%

As of 14 June 2026, RetinalGenix Technologies Inc. has a market cap of $59.54M USD, ranking #29296 globally and #4340 in the United States. It ranks #2651 in the Healthcare sector, and #546 in the Medical Devices industry.

Global Rank

29296

Country Rank

4340

Sector Rank

2651

Industry Rank

546

Key Stats

Market Cap

$59.54MUSD

Enterprise Value

$60.14MUSD

EBITDA (TTM)

-$2.42MUSD

Net Income (TTM)

-$2.43MUSD

PB Ratio

-25.9

Company Profile

Country (HQ)

United States

Sector

Healthcare

Industry

Medical Devices

CEO

Jerry Katzman open_in_new

Founded

2017

Website

retinalgenix.com open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
-9.9%	-9.9%	-9.6%	-9.6%	-36%	-39%	-8.6%	-62%	-20%

News

Markets

Exchange	Ticker	Price	Quotes
OTC Markets (OTCMKTS / OTC) MIC: OTCM PRIMARY	RTGN RetinalGenix Technologies Inc ISIN: US76133Y1055 Shares Out.: Shares Outstanding: 18.755M¹ Shares Float: 6.163M² TV: TradingView: OTC: RTGN SA: Stock Analysis: OTC: RTGN YF: Yahoo Finance: RTGN GF: Google Finance: OTCMKTS: RTGN BA: Barron's: RTGN MS: Morningstar: PINX: RTGN	3.20 USD	TV: TradingView: OTC: RTGN SA: Stock Analysis: OTC: RTGN YF: Yahoo Finance: RTGN GF: Google Finance: OTCMKTS: RTGN BA: Barron's: RTGN MS: Morningstar: PINX: RTGN

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About RetinalGenix Technologies Inc.

RetinalGeniX Technologies Inc., an ophthalmic research and development company, focuses on developing technologies to screen, monitor, diagnose, and treat ophthalmic, optical, and sight-threatening disorders. Its products include the Retinal Imaging Screening Device, a portable retinal imaging system providing a wide field of view without requiring pupil dilation; and RetinalCam, an in-home/remote location patient-activated monitoring and imaging device offering real-time communication and alerting system for physicians. It also develops RTG-2023 for the treatment of dry age-related macular degeneration; and RTG-2024 for the treatment of Alzheimer’s syndrome dementia. The company was incorporated in 2017 and is based in Apollo Beach, Florida. RetinalGenix Technologies Inc. is a subsidiary of Sanovas Ophthalmology, LLC.

Similar Companies

Industry: Medical Devices (United States)

Name	Market Cap (USD) diff.	PE	Country
Thermo Fisher Scientific Inc. NYSE: TMO	$173.27B 291K%	25.8	United States
Intuitive Surgical, Inc. NASDAQ: ISRG	$160.73B 270K%	56.7	United States
Abbott Laboratories NYSE: ABT	$159.07B 267K%	25.6	United States
Danaher Corp. NYSE: DHR	$126.55B 212K%	34.7	United States
Stryker Corp. NYSE: SYK	$120.69B 203K%	38.3	United States
Boston Scientific Corp. NYSE: BSX	$84.93B 143K%	24.5	United States

Industry: Medical Devices (Global)

Name	Market Cap (USD) diff.	PE	Country
Medtronic plc NYSE: MDT	$101.9B 171K%	22.2	Ireland
EssilorLuxottica Société anonyme EPA: EL	$97.46B 84.32B EUR 164K%	36.7	France
HOYA Corp. TSE: 7741	$61.41B 9.83T JPY 103K%	40.0	Japan
Siemens Healthineers AG XETRA: SHL	$45.47B 39.34B EUR 76K%	18.7	Germany
Alcon Inc. SIX: ALC	$36.38B 28.99B CHF 61K%	37.9	Switzerland
Shenzhen Mindray Bio-Medical Electronics Co., Ltd. SHE: 300760	$30.06B 203.66B CNY 50K%	26.0	China

chevron_leftBack